Stockscreener 앱 받기
2.16
1.60%
-0.03
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell 3000E Growth Benchmark - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell 3000E Index - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell Microcap Index - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Form 4 Spero Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
Spero Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPRO) - TradingView
Spero Therapeutics, Inc. Actuals & Estimates (BOATS:SPRO) - TradingView
Spero Therapeutics Expands Stock Incentive Plan and Authorization - The Globe and Mail
Spero Therapeutics (SPRO) director awarded RSUs and 20,000-share option - Stock Titan
Spero Therapeutics (SPRO) director receives RSU and stock option awards - Stock Titan
Spero Therapeutics (SPRO) director receives 10,000 RSUs and 20,000-share option grant - Stock Titan
Spero Therapeutics (SPRO) director awarded RSUs and stock options - Stock Titan
Spero Therapeutics (SPRO) grants director RSUs and 20,000 stock options - Stock Titan
Equity awards to Spero (NASDAQ: SPRO) director Scott Jackson - Stock Titan
Spero Therapeutics (SPRO) director receives RSU and 20,000-share option grant - Stock Titan
Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock plan - Stock Titan
SPRO Forecast — Price Target — Prediction for 2027 - TradingView
Spero Therapeutics (SPRO) Slips 3.81% as Selling Pressure Tests Key Support LevelsSystematic Flow - dars.gov.et
Spero Therapeutics Inc (SPRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
FDA clears Spero (NASDAQ: SPRO) oral Utebzi antibiotic for complicated UTIs - Stock Titan
Spero Therapeutics Inc (NASDAQ: SPRO) Share Price, SPRO Stock News, SPRO Share Price & Updates - Kalkine
US FDA approves GSK's oral antibiotic for drug-resistant UTIs - Reuters
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics Stock: Antibiotic Development In Focus - Kalkine Media
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections - TradingView
Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO) - Yahoo Finance
Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spero Therapeutics Inc (SPRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spero Therapeutics Inc (SPRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - Benzinga
AlTi Global And 2 Other Promising Penny Stocks To Watch - simplywall.st
Spero Therapeutics and GSK Announce FDA Approval of Utebzi, the First Oral Carbapenem Antibiotic for Complicated Urinary Tract Infections in the US - Quiver Quantitative
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) - GlobeNewswire
FDA approves first oral carbapenem for complicated UTIs in adults - Stock Titan
GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections - Moomoo
GSK, Spero Therapeutics Gain U.S. Approval for Utebzi - marketscreener.com
SPRO Stock Slumps As Volatility Grips Small-Cap Biotech - timothysykes.com
Spero Therapeutics Approaches Key FDA Decision For Tebipenem HBr In CUTIs - RTTNews
Spero Therapeutics Inc (SPRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spero Therapeutics Inc (SPRO) Institutional Confidence - TradingKey
Spero Therapeutics Inc (SPRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spero Therapeutics Inc (SPRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Spero Therapeutics Inc (SPRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Spero Therapeutics Stock (US85208T1079): Quiet session keeps focus on fundamentals and pipeline - AD HOC NEWS
SPRO Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentSlow Growth Warning - dars.gov.et
SPRO News | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold) - Seeking Alpha
Spero Therapeutics Inc. Q1 2026 Earnings: Better-Than-Expected Loss Provides Little Respite as Shares FallMargin Guidance - dars.gov.et
Spero Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls Amid Lack of Revenue - newsline.com
MSN Money - MSN
Spero Therapeutics (SPRO) Slips 2.41% as Stock Tests Key Support at $2.69Dark Pool Volume - newsline.com
Spero Therapeutics (SPRO) Hovers Near Support Amid Modest Decline – Key Levels in FocusCorrective Wave - The Legal Advocate
Compass Pathways elects Kathleen Tregoning to board - Investing.com
Spero Therapeutics (SPRO) Jumps 4.9% as Stock Approaches Key Resistance at $3.15Oversold Bounce Ideas - The Legal Advocate
SPROSpero Therapeutics Inc Stock Price and Quote - Finviz
SPRO Technical Analysis | Trend, Signals & Chart Patterns | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics (SPRO) Q1 2026 Earnings: Why the Beat MattersCEO Earnings Statement - Newser
Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price Today & Analysis - Gotrade
Promising Penny Stocks To Consider In May 2026 - simplywall.st
1.47%
2.69%
자본화:
|
볼륨(24시간):